| Product Code: ETC8870290 | Publication Date: Sep 2024 | Updated Date: Aug 2025 | Product Type: Market Research Report | |
| Publisher: 6Wresearch | Author: Dhaval Chaurasia | No. of Pages: 75 | No. of Figures: 35 | No. of Tables: 20 |
1 Executive Summary |
2 Introduction |
2.1 Key Highlights of the Report |
2.2 Report Description |
2.3 Market Scope & Segmentation |
2.4 Research Methodology |
2.5 Assumptions |
3 Poland Pharmacogenetics Testing in Psychiatry/Depression Market Overview |
3.1 Poland Country Macro Economic Indicators |
3.2 Poland Pharmacogenetics Testing in Psychiatry/Depression Market Revenues & Volume, 2021 & 2031F |
3.3 Poland Pharmacogenetics Testing in Psychiatry/Depression Market - Industry Life Cycle |
3.4 Poland Pharmacogenetics Testing in Psychiatry/Depression Market - Porter's Five Forces |
3.5 Poland Pharmacogenetics Testing in Psychiatry/Depression Market Revenues & Volume Share, By Type, 2021 & 2031F |
3.6 Poland Pharmacogenetics Testing in Psychiatry/Depression Market Revenues & Volume Share, By Test Type, 2021 & 2031F |
3.7 Poland Pharmacogenetics Testing in Psychiatry/Depression Market Revenues & Volume Share, By Gene Type, 2021 & 2031F |
3.8 Poland Pharmacogenetics Testing in Psychiatry/Depression Market Revenues & Volume Share, By Patient Type, 2021 & 2031F |
3.9 Poland Pharmacogenetics Testing in Psychiatry/Depression Market Revenues & Volume Share, By Product, 2021 & 2031F |
3.10 Poland Pharmacogenetics Testing in Psychiatry/Depression Market Revenues & Volume Share, By End User, 2021 & 2031F |
3.11 Poland Pharmacogenetics Testing in Psychiatry/Depression Market Revenues & Volume Share, By Distribution Channel, 2021 & 2031F |
4 Poland Pharmacogenetics Testing in Psychiatry/Depression Market Dynamics |
4.1 Impact Analysis |
4.2 Market Drivers |
4.2.1 Increasing prevalence of psychiatric disorders and depression in Poland |
4.2.2 Growing awareness and acceptance of pharmacogenetic testing in healthcare |
4.2.3 Advancements in genetic testing technologies and data analysis techniques |
4.3 Market Restraints |
4.3.1 High cost associated with pharmacogenetic testing |
4.3.2 Limited reimbursement policies for genetic testing in psychiatry |
4.3.3 Lack of skilled healthcare professionals trained in interpreting genetic test results |
5 Poland Pharmacogenetics Testing in Psychiatry/Depression Market Trends |
6 Poland Pharmacogenetics Testing in Psychiatry/Depression Market, By Types |
6.1 Poland Pharmacogenetics Testing in Psychiatry/Depression Market, By Type |
6.1.1 Overview and Analysis |
6.1.2 Poland Pharmacogenetics Testing in Psychiatry/Depression Market Revenues & Volume, By Type, 2021- 2031F |
6.1.3 Poland Pharmacogenetics Testing in Psychiatry/Depression Market Revenues & Volume, By Anxiety, 2021- 2031F |
6.1.4 Poland Pharmacogenetics Testing in Psychiatry/Depression Market Revenues & Volume, By Mood Disorders, 2021- 2031F |
6.1.5 Poland Pharmacogenetics Testing in Psychiatry/Depression Market Revenues & Volume, By Depression, 2021- 2031F |
6.1.6 Poland Pharmacogenetics Testing in Psychiatry/Depression Market Revenues & Volume, By Bipolar Disorders, 2021- 2031F |
6.1.7 Poland Pharmacogenetics Testing in Psychiatry/Depression Market Revenues & Volume, By Psychotic Disorders, 2021- 2031F |
6.1.8 Poland Pharmacogenetics Testing in Psychiatry/Depression Market Revenues & Volume, By Eating Disorders, 2021- 2031F |
6.2 Poland Pharmacogenetics Testing in Psychiatry/Depression Market, By Test Type |
6.2.1 Overview and Analysis |
6.2.2 Poland Pharmacogenetics Testing in Psychiatry/Depression Market Revenues & Volume, By Whole Genome Sequencing, 2021- 2031F |
6.2.3 Poland Pharmacogenetics Testing in Psychiatry/Depression Market Revenues & Volume, By Chromosomal Array-Based Tests, 2021- 2031F |
6.3 Poland Pharmacogenetics Testing in Psychiatry/Depression Market, By Gene Type |
6.3.1 Overview and Analysis |
6.3.2 Poland Pharmacogenetics Testing in Psychiatry/Depression Market Revenues & Volume, By CYP2C19, 2021- 2031F |
6.3.3 Poland Pharmacogenetics Testing in Psychiatry/Depression Market Revenues & Volume, By CYP2C9 AND VKORC1, 2021- 2031F |
6.3.4 Poland Pharmacogenetics Testing in Psychiatry/Depression Market Revenues & Volume, By CYP2D6, 2021- 2031F |
6.3.5 Poland Pharmacogenetics Testing in Psychiatry/Depression Market Revenues & Volume, By HLA-B, 2021- 2031F |
6.3.6 Poland Pharmacogenetics Testing in Psychiatry/Depression Market Revenues & Volume, By HTR2A/C, 2021- 2031F |
6.3.7 Poland Pharmacogenetics Testing in Psychiatry/Depression Market Revenues & Volume, By HLA-A, 2021- 2031F |
6.4 Poland Pharmacogenetics Testing in Psychiatry/Depression Market, By Patient Type |
6.4.1 Overview and Analysis |
6.4.2 Poland Pharmacogenetics Testing in Psychiatry/Depression Market Revenues & Volume, By Child, 2021- 2031F |
6.4.3 Poland Pharmacogenetics Testing in Psychiatry/Depression Market Revenues & Volume, By Adult, 2021- 2031F |
6.4.4 Poland Pharmacogenetics Testing in Psychiatry/Depression Market Revenues & Volume, By Geriatric, 2021- 2031F |
6.5 Poland Pharmacogenetics Testing in Psychiatry/Depression Market, By Product |
6.5.1 Overview and Analysis |
6.5.2 Poland Pharmacogenetics Testing in Psychiatry/Depression Market Revenues & Volume, By Instruments, 2021- 2031F |
6.5.3 Poland Pharmacogenetics Testing in Psychiatry/Depression Market Revenues & Volume, By Consumables, 2021- 2031F |
6.5.4 Poland Pharmacogenetics Testing in Psychiatry/Depression Market Revenues & Volume, By Software & Services, 2021- 2031F |
6.6 Poland Pharmacogenetics Testing in Psychiatry/Depression Market, By End User |
6.6.1 Overview and Analysis |
6.6.2 Poland Pharmacogenetics Testing in Psychiatry/Depression Market Revenues & Volume, By Hospitals & Clinics, 2021- 2031F |
6.6.3 Poland Pharmacogenetics Testing in Psychiatry/Depression Market Revenues & Volume, By Dignostics Laboratories, 2021- 2031F |
6.6.4 Poland Pharmacogenetics Testing in Psychiatry/Depression Market Revenues & Volume, By Academic And Research Institutes, 2021- 2031F |
6.6.5 Poland Pharmacogenetics Testing in Psychiatry/Depression Market Revenues & Volume, By Others, 2021- 2031F |
6.7 Poland Pharmacogenetics Testing in Psychiatry/Depression Market, By Distribution Channel |
6.7.1 Overview and Analysis |
6.7.2 Poland Pharmacogenetics Testing in Psychiatry/Depression Market Revenues & Volume, By Direct Tender, 2021- 2031F |
6.7.3 Poland Pharmacogenetics Testing in Psychiatry/Depression Market Revenues & Volume, By Third-Party Distribution, 2021- 2031F |
6.7.4 Poland Pharmacogenetics Testing in Psychiatry/Depression Market Revenues & Volume, By Others, 2021- 2031F |
6.7.5 Poland Pharmacogenetics Testing in Psychiatry/Depression Market Revenues & Volume, By Others, 2021- 2031F |
7 Poland Pharmacogenetics Testing in Psychiatry/Depression Market Import-Export Trade Statistics |
7.1 Poland Pharmacogenetics Testing in Psychiatry/Depression Market Export to Major Countries |
7.2 Poland Pharmacogenetics Testing in Psychiatry/Depression Market Imports from Major Countries |
8 Poland Pharmacogenetics Testing in Psychiatry/Depression Market Key Performance Indicators |
8.1 Adoption rate of pharmacogenetic testing in psychiatry/depression treatment |
8.2 Number of healthcare facilities offering pharmacogenetic testing services |
8.3 Patient satisfaction and outcomes improvement post pharmacogenetic testing |
9 Poland Pharmacogenetics Testing in Psychiatry/Depression Market - Opportunity Assessment |
9.1 Poland Pharmacogenetics Testing in Psychiatry/Depression Market Opportunity Assessment, By Type, 2021 & 2031F |
9.2 Poland Pharmacogenetics Testing in Psychiatry/Depression Market Opportunity Assessment, By Test Type, 2021 & 2031F |
9.3 Poland Pharmacogenetics Testing in Psychiatry/Depression Market Opportunity Assessment, By Gene Type, 2021 & 2031F |
9.4 Poland Pharmacogenetics Testing in Psychiatry/Depression Market Opportunity Assessment, By Patient Type, 2021 & 2031F |
9.5 Poland Pharmacogenetics Testing in Psychiatry/Depression Market Opportunity Assessment, By Product, 2021 & 2031F |
9.6 Poland Pharmacogenetics Testing in Psychiatry/Depression Market Opportunity Assessment, By End User, 2021 & 2031F |
9.7 Poland Pharmacogenetics Testing in Psychiatry/Depression Market Opportunity Assessment, By Distribution Channel, 2021 & 2031F |
10 Poland Pharmacogenetics Testing in Psychiatry/Depression Market - Competitive Landscape |
10.1 Poland Pharmacogenetics Testing in Psychiatry/Depression Market Revenue Share, By Companies, 2024 |
10.2 Poland Pharmacogenetics Testing in Psychiatry/Depression Market Competitive Benchmarking, By Operating and Technical Parameters |
11 Company Profiles |
12 Recommendations |
13 Disclaimer |
Export potential enables firms to identify high-growth global markets with greater confidence by combining advanced trade intelligence with a structured quantitative methodology. The framework analyzes emerging demand trends and country-level import patterns while integrating macroeconomic and trade datasets such as GDP and population forecasts, bilateral import–export flows, tariff structures, elasticity differentials between developed and developing economies, geographic distance, and import demand projections. Using weighted trade values from 2020–2024 as the base period to project country-to-country export potential for 2030, these inputs are operationalized through calculated drivers such as gravity model parameters, tariff impact factors, and projected GDP per-capita growth. Through an analysis of hidden potentials, demand hotspots, and market conditions that are most favorable to success, this method enables firms to focus on target countries, maximize returns, and global expansion with data, backed by accuracy.
By factoring in the projected importer demand gap that is currently unmet and could be potential opportunity, it identifies the potential for the Exporter (Country) among 190 countries, against the general trade analysis, which identifies the biggest importer or exporter.
To discover high-growth global markets and optimize your business strategy:
Click Here